Lykos’ MDMA-assisted PTSD treatment rejected by FDA after troubled trial and pushback from experts

The FDA has rejected Lykos’ MDMA-assisted treatment for patients with post-traumatic stress disorder, a major setback for the company that had hoped to translate more …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Moderna wants an accelerated approval for its cancer vaccine — but it’s waiting on three things

Moderna has touted the possibility of an accelerated approval for its Merck-partnered cancer vaccine by 2025. But according to executives, three things need to happen

February 23, 2024

Cybin Acquires Entheon’s DMT Trial, Numi’s Novamind Acq. Complete, Bad News for MindMed and More

June 14, 2022

Medacta’s QUADRA-H hip stem achieves 13A* exemplary quality rating from the British Orthopaedic Data Evaluation Panel (ODEP) – Biotech Investments

Medacta Group SA / Key word(s): Miscellaneous Medacta’s QUADRA-H hip stem achieves 13A* exemplary quality rating from the British Orthopaedic Data Evaluation Panel (ODEP) 08.01.2024

January 9, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.